Cagrilintide News New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk

Why “cagrilintide news” matters more now than last year

If you manage obesity or advise patients in real clinic conditions, you’ve probably seen the same pattern: people start a weight-loss plan, the appetite suppression helps at first, and then results stall—often because adherence, side effects, or modest average outcomes don’t translate into the weight change patients actually need.

That’s why the latest cagrilintide news from the New England Journal of Medicine caught my attention: two Phase 3a REDEFINE trials reported results for cagrilintide–semaglutide (a once-weekly fixed combination often discussed as CagriSema) for adults with overweight/obesity, including those with type 2 diabetes. The headline is straightforward—greater mean weight loss than placebo—but the “how” (dual-mechanism biology, trial design, and safety profile) is what makes this news clinically actionable.

What NEJM reported on August 14, 2025 (REDEFINE 1 and REDEFINE 2)

NEJM published the results simultaneously in the August 14, 2025 issue. There were two Phase 3a trials with 68-week treatment periods and placebo-controlled designs: one in adults without diabetes (REDEFINE 1) and one in adults with type 2 diabetes (REDEFINE 2).

REDEFINE 1: Overweight or obesity without diabetes

In REDEFINE 1, adults without diabetes were randomized to receive once-weekly cagrilintide–semaglutide 2.4 mg/2.4 mg, semaglutide alone, cagrilintide alone, or placebo—each alongside lifestyle interventions. The trial’s coprimary endpoints included both relative body-weight change and the proportion achieving at least 5% weight loss by week 68 (with additional confirmatory thresholds at 20%, 25%, and 30%).

• Mean weight change at week 68: -20.4% with cagrilintide–semaglutide vs -3.0% with placebo (estimated difference -17.3 percentage points; P<0.001).
• Weight-loss targets: patients were more likely to reach ≥5%, ≥20%, ≥25%, and ≥30% targets vs placebo (P<0.001 for all comparisons).
• GI tolerability: gastrointestinal adverse events occurred more often with combination therapy (about 79.6%) than placebo (about 39.9%), described as mainly transient and mild-to-moderate.

REDEFINE 2: Overweight or obesity with type 2 diabetes

REDEFINE 2 studied adults with type 2 diabetes (HbA1c 7–10% and BMI ≥27) randomized in a 3:1 ratio to once-weekly cagrilintide–semaglutide 2.4 mg/2.4 mg or placebo, again with lifestyle intervention for 68 weeks. Primary endpoints focused on percent change in body weight and the proportion achieving at least 5% weight loss, plus glycemic and safety outcomes.

• Mean weight change at week 68: -13.7% with cagrilintide–semaglutide vs -3.4% with placebo (estimated difference -10.4 percentage points; P<0.001).
• Weight-loss thresholds: higher proportions achieved ≥5% and also ≥10%, ≥15%, and ≥20% reductions (P<0.001 for comparisons).
• Glycemic outcomes: a substantially larger share reached HbA1c ≤6.5% (73.5% vs 15.9%).
• GI events: gastrointestinal adverse events were reported by 72.5% vs 34.4% (most transient and mild-to-moderate).

How cagrilintide–semaglutide is supposed to work (and why the combo makes mechanistic sense)

When I review new anti-obesity pharmacotherapy, I look for coherence between mechanism and trial endpoints. Here, the logic is that cagrilintide and semaglutide may complement each other’s effects on appetite regulation.

NEJM’s framing in the REDEFINE program highlights that the combination can produce substantial weight reduction through complementary actions affecting appetite regulation pathways, including brain regions implicated in both hedonic (pleasure/drive) and homeostatic (energy balance) appetite control. In my experience, that kind of “two-side” appetite modulation is exactly what can reduce the common failure mode of monotherapy—where appetite suppression alone helps early but doesn’t fully address eating behavior drivers over time.

From a practical standpoint: what this means for counseling

Even when average outcomes look strong, real-world results depend on managing tolerability and expectations. In these trials, GI adverse events were notably more frequent with the combination than placebo, but were described as mainly transient and mild-to-moderate—so the clinical job becomes anticipating, planning for, and supporting adherence rather than reacting after the first side effects show up.

What I’d tell stakeholders: benefits, limitations, and decision points

Here’s the balanced view I’d use when translating cagrilintide news into patient and stakeholder decisions.

Benefits that stand out

• Magnitude vs placebo: both trials showed clinically meaningful separation in mean weight loss by week 68.
• Target-based outcomes: proportion reaching ≥20%, ≥25%, and ≥30% thresholds (REDEFINE 1) and higher ≥10–20% thresholds (REDEFINE 2) supports that results aren’t only “average” driven.
• Diabetes relevance: REDEFINE 2 linked weight loss with a large share achieving HbA1c ≤6.5% at 68 weeks.

Limitations and trade-offs to consider

• GI side effects are common: the combination showed substantially higher GI adverse event rates than placebo in both trials.
• Not “same for everyone”: trial data emphasize thresholds and responder distributions—so you should plan for variability in individual response rather than assuming uniform outcomes.
• Status of approval: the NEJM publications discuss these as investigational findings within the REDEFINE program (not a blanket claim about real-world prescribing availability).

Key SEO takeaways: what to say (and what not to overstate)

If you’re writing about this topic for search, the most trustworthy angle is to mirror the way the evidence is presented: specify trial population, dose, duration (68 weeks), and the endpoints (mean percent weight change and ≥5% weight loss, with additional thresholds). That’s how you earn both rankings and reader trust.

What I recommend avoiding: vague language like “cures obesity” or “best without trade-offs.” Even in a strong dataset, the GI tolerability profile is real, and decision-making should reflect it.

FAQ

What does the newest cagrilintide news actually show?

NEJM’s August 14, 2025 REDEFINE 1 and REDEFINE 2 Phase 3a results report that once-weekly cagrilintide–semaglutide 2.4 mg/2.4 mg produced significantly greater weight loss than placebo at 68 weeks in adults with overweight/obesity, including those with type 2 diabetes; GI adverse events were more common than with placebo.

Is the combination therapy only for people with diabetes?

No. REDEFINE 1 studied adults without diabetes, and REDEFINE 2 studied adults with type 2 diabetes; both showed weight-loss benefit versus placebo, with diabetes patients also showing substantial HbA1c improvement.

Why do trials report both mean weight change and weight-loss “targets”?

Mean change can conceal how many people meaningfully respond. Target thresholds (like ≥5%, ≥20%, ≥25%, and ≥30%) help quantify clinical relevance and responder rates, which is often what clinicians and patients care about most when deciding whether a therapy is worth continuing.

Conclusion: the actionable next step

The August 14, 2025 NEJM publications add meaningful, trial-grade evidence to the growing field of dual-injectable anti-obesity approaches—showing substantial mean weight loss with cagrilintide–semaglutide at 68 weeks in both non-diabetes and type 2 diabetes populations, alongside a consistent GI tolerability pattern.

Next step: If you’re tracking this for content or clinical strategy, build your update around the exact trial details—population, dose (2.4 mg/2.4 mg), duration (68 weeks), and the primary endpoint results (mean weight change plus ≥5% loss)—so your audience gets both accuracy and clarity.